Search details
1.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 16(7): 859-70, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-26095784
2.
Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib.
J Adv Pract Oncol
; 14(7): 598-607, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-38196672
3.
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
Eur J Cancer
; 168: 91-98, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35487183
4.
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Clin Cancer Res
; 27(17): 4848-4858, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-34108184
5.
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Clin Cancer Res
; 15(1): 355-60, 2009 Jan 01.
Article
in English
| MEDLINE | ID: mdl-19118065
6.
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Eur J Cancer
; 130: 219-227, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32234665
7.
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
ESMO Open
; 5(4)2020 08.
Article
in English
| MEDLINE | ID: mdl-32847838
8.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
J Clin Oncol
; 38(26): 2960-2970, 2020 09 10.
Article
in English
| MEDLINE | ID: mdl-32716739
9.
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 37(36): 3518-3527, 2019 12 20.
Article
in English
| MEDLINE | ID: mdl-31689155
10.
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
JCO Precis Oncol
; 7: e2100489, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37079860
11.
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Cancer Med
; 6(9): 2042-2051, 2017 Sep.
Article
in English
| MEDLINE | ID: mdl-28801995
12.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Eur J Cancer
; 81: 17-25, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28591675
13.
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Lung Cancer
; 54(1): 69-77, 2006 Oct.
Article
in English
| MEDLINE | ID: mdl-16934909
14.
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
Eur J Cancer
; 100: 135-136, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29970352
15.
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Cancer
; 110(5): 965-72, 2007 Sep 01.
Article
in English
| MEDLINE | ID: mdl-17614302
Results
1 -
15
de 15
1
Next >
>>